# Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

> **NCT00620971** · PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 77 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00620971
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2014-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620971, "Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00620971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*